Avenciguat

DB18882InvestigationalSmall molecule

Avenciguat is under investigation in clinical trial NCT05282121 (A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis...

Mechanism: Pharmacologically active on Guanylate cyclase
Curator reviewed
Formula / weight: C₃₄H₃₈N₄O₅ · 582.701 g/mol (avg)
Code names: BI 685509

Resolves to

Compound

UNIIZA7KTB4PSPCAS1579514-06-9

Structure

InChIKeyKWNFFNFBUMFTHK-UHFFFAOYSA-NSMILESCCOC1=C(C=NN1C1=CC=CC(=N1)C1=CC=CC(C)=C1OCC1=CC=C2CN(CCC2=C1C)C1CCOCC1)C(O)=O

Transporters

Q9Y6L6SLCO1B1P08183ABCB1Q9NPD5SLCO1B3

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3TransportersSubstrate / inhibitor direction, not just membership

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which companies are running trials of Avenciguat, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account